SCHEDULE: Janus Henderson Discloses 12.1% Stake in INVIVYD

Janus Henderson Group PLC and its affiliates reported a 12.1% beneficial ownership stake in INVIVYD, INC. common stock as of September 30, 2025.

Summary

• Janus Henderson Group PLC, a Jersey-based entity, and its affiliates, including Janus Henderson Biotech Innovation Master Fund Ltd, reported beneficial ownership of INVIVYD, INC. common stock.
• Janus Henderson Group PLC beneficially owns 25,383,077 shares, representing 12.1% of the class.
• Janus Henderson Biotech Innovation Master Fund Ltd beneficially owns 21,576,145 shares, representing 10.3% of the class.
• Both entities hold shared voting and shared dispositive power over their respective reported shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of INVIVYD, INC.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A significant institutional stake by a reputable asset manager like Janus Henderson is generally viewed favorably, indicating confidence, but the filing itself is purely informational about ownership, not performance.

Positives

• The presence of a significant institutional investor like Janus Henderson can be seen as a positive signal of confidence in INVIVYD, INC.'s long-term prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investment in INVIVYD, INC., a common occurrence in the biotech sector where specialized funds often take substantial positions in companies with promising pipelines or technologies. Such investments can provide stability and long-term support for the company.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by Janus Henderson as a vote of confidence, potentially enhancing market perception and stability.
• The filing does not directly impact employees, customers, suppliers, or creditors, as it pertains solely to beneficial ownership disclosure.

Key Dates

Recommendation

This Schedule 13G filing is a disclosure of beneficial ownership by an institutional investor and does not contain information related to the company's operational performance, financial health, or strategic direction that would warrant a 'buy' or 'sell' recommendation. The presence of a significant institutional holder like Janus Henderson is generally a neutral to slightly positive signal, suggesting a 'hold' recommendation for existing investors to await further fundamental news.

Keywords

INVIVYD, Janus Henderson, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotech